Table 1 Patient characteristics for the Stanford-HCC and TCGA-HCC datasets.
Patient characteristic | TCGA-HCC development cohort (n = 299) | TCGA-HCC test cohort (n = 53) | Stanford-HCC (n = 198) |
|---|---|---|---|
Training and validation set | Internal test set | External test set | |
Age (at surgery) (years) | 60 (51, 68) | 61 (51, 68) | 64 (57, 69) |
Gender | |||
Male | 206 (69%) | 33 (62%) | 157 (79%) |
Female | 93 (31%) | 20 (38%) | 41 (21%) |
Hepatitis B virus infection | |||
Negative | 195 (68%) | 33 (67%) | 147 (74%) |
Positive | 90 (32%) | 16 (33%) | 51 (26%) |
Unknown | 14 | 4 | 0 |
Hepatitis C virus infection | |||
Negative | 243 (85%) | 41 (84%) | 96 (48%) |
Positive | 42 (15%) | 8 (16%) | 102 (52%) |
Unknown | 14 | 4 | 0 |
Alcohol intake | |||
Negative | 188 (66%) | 30 (61%) | 181 (91%) |
Positive | 97 (34%) | 19 (39%) | 17 (8.6%) |
Unknown | 14 | 4 | 0 |
Non-alcoholic fatty liver disease | |||
Negative | 271 (95.1%) | 44 (90%) | 184 (93%) |
Positive | 14 (4.9%) | 5 (10%) | 14 (7.1%) |
Unknown | 14 | 4 | 0 |
AJCC stage grouping | |||
IA | 8 (2.7%) | 1 (1.9%) | 44 (22%) |
IB | 121 (41%) | 24 (46%) | 66 (33%) |
II | 85 (29%) | 16 (31%) | 68 (34%) |
IIIA | 60 (20%) | 9 (17%) | 11 (5.6%) |
IIIB | 16 (5.4%) | 1 (1.9%) | 7 (3.5%) |
IVA | 3 (1.0%) | 0 (0%) | 2 (1%) |
IVB | 1 (0.3%) | 1 (1.9%) | 0 (0%) |
Unknown | 5 | 1 | 0 |
Largest tumor diameter (mm) | 65 (35, 100) | 55 (34, 100) | 30 (18, 50) |
Unknown | 5 | 0 | 0 |
Tumor multifocality | |||
Negative | 207 (69%) | 38 (73%) | 142 (72%) |
Positive | 91 (31%) | 14 (27%) | 56 (28%) |
Unknown | 1 | 1 | 0 |
Histologic grade | |||
Well-differentiated | 46 (15%) | 5 (9.4%) | 63 (32%) |
Moderately-differentiated | 162 (54%) | 32 (60%) | 108 (55%) |
Poorly-differentiated | 89 (30%) | 16 (30%) | 26 (13%) |
Undifferentiated | 2 (0.7%) | 0 (0%) | 1 (0.5%) |
Microvascular invasion | |||
Negative | 196 (67%) | 36 (68%) | 147 (74%) |
Positive | 95 (33%) | 17 (32%) | 51 (26%) |
Unknown | 8 | 0 | 0 |
Macrovascular invasion | |||
Negative | 271 (93%) | 49 (92%) | 188 (96%) |
Positive | 21 (7.2%) | 4 (7.5%) | 8 (4.1%) |
Unknown | 7 | 0 | 0 |
Surgical margin status | |||
Negative | 249 (94%) | 45 (88%) | 192 (97%) |
Positive | 17 (6.4%) | 6 (12%) | 5 (2.5%) |
Unknown | 33 | 2 | 0 |
Fibrosis stage | |||
0 | 77 (33%) | 13 (30%) | 38 (19%) |
1 | 11 (4.8%) | 2 (4.5%) | 13 (6.6%) |
2 | 25 (11%) | 4 (9.1%) | 15 (7.6%) |
3 | 26 (11%) | 6 (14%) | 13 (6.6%) |
4 | 91 (40%) | 19 (43%) | 119 (60%) |
Unknown | 69 | 9 | 0 |
Recurrence | |||
No | 148 (49%) | 28 (53%) | 136 (69%) |
Yes | 151 (51%) | 25 (47%) | 62 (31%) |
Length of follow-up (months) | 12 (4, 24) | 13 (6, 20) | 25 (9, 48) |
Risk score | 0.07 (− 0.26, 0.30) | − 0.31 (− 0.46, − 0.15) | |
